Form 4: Alzamend Neuro Director Sells Over 44,000 Shares

Milton C. Ault III, a Director and 10% Owner of Alzamend Neuro, Inc., reported selling a total of 44,843 shares of common stock in late July 2025.

Summary

• Milton C. Ault III, a Director and 10% Owner of Alzamend Neuro, Inc. (ALZN), sold shares of common stock.
• On July 25, 2025, 36,532 shares were sold at a volume-weighted average price of $2.8976 per share, with prices ranging from $2.891 to $2.9129.
• On July 28, 2025, an additional 8,311 shares were sold at a price of $2.6849 per share.
• Following these transactions, beneficial ownership includes 1,843 shares held directly, 37,709 shares indirectly through Ault Lending, LLC, 11,068 shares indirectly through Ault Life Sciences, Inc., and 61 shares indirectly through Ault Life Sciences Fund, LLC.
• The total number of shares sold across both transactions is 44,843.

Sentiment

Score: 3

Explanation: The filing reports significant insider selling by a director and 10% owner, Milton C. Ault III, which is typically viewed as a negative signal by investors as it may indicate a lack of confidence in the company's future performance or valuation. The decreasing sale prices further reinforce this negative sentiment.

Negatives

• A Director and 10% Owner, Milton C. Ault III, sold a significant number of shares (44,843 shares) of Alzamend Neuro common stock.
• The sales occurred at decreasing prices, from a volume-weighted average of $2.8976 on July 25, 2025, to $2.6849 on July 28, 2025.

Risks

• Insider selling by a director and significant shareholder may signal a lack of confidence in the company's near-term prospects or valuation by the insider.
• The sale of shares could put downward pressure on the stock price due to market perception of insider sentiment.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance; it is a historical report of insider transactions.

Industry Context

Insider selling, particularly by a director and significant owner, can be interpreted by the market as a signal regarding the company's future prospects or current valuation. In the biotechnology or pharmaceutical industry (implied by 'Neuro'), such sales might be scrutinized more closely, especially if the company is in clinical development stages or awaiting regulatory approvals, as insider sentiment can be a key indicator.

Comparison to Industry Standards

• This filing reports insider transactions and does not provide financial results or operational metrics that can be directly compared to industry standards or specific comparable companies/projects.
• Insider selling is a common occurrence across all industries, but its significance depends on the individual's role, the volume of shares sold relative to their total holdings, and the timing in relation to company news or market events.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• Management/Employees: Could face questions regarding the insider's rationale for selling, potentially impacting morale if not clearly communicated.

Key Dates

Recommendation

The sale of a significant number of shares by a director and 10% owner, especially at declining prices, typically signals a lack of confidence in the company's near-term prospects or current valuation. This insider selling could exert downward pressure on the stock price and suggests that the insider believes the current price is a good exit point.

Keywords

Alzamend Neuro, ALZN, Milton C. Ault III, insider trading, Form 4, stock sale, director, 10% owner, beneficial ownership, Ault Lending, Ault Life Sciences